Replies to post #202482 on Biotech Values

[CHM_760]

Let me re-phrase my question. Instead of "resistant to the concept" substitute "dismissive of the concept".

Your own post, to which I was replying, stated

What are you insuring against, exactly? If you pull the switch and thereby deactivate the immunotherapy, the patient will presumably die from the underlying disease. (It’s not realistic to think that such a patient could be switched to a different curative therapy.)

In ZIOP/XON's case, when you "pull the switch" OFF and "deactivate the immunotherapy", you can put the switch back ON over the next days with an oral pill and RE-activate the therapy. And yet every post this morning about switches has discussed only approaches that are suicide switches that do not work like ZIOP/XON.

I consider the old-timers on this board to be pretty savvy, so I again ask: why so totally dismissive of the Rheoswitch? I find it hard to believe that no-one here has ever heard of their current clinical trial(s), so you MUST have dismissed it out of hand for one reason or another. I'm just truly curious.